AlphaGrep UK Ltd Buys New Position in Zoetis Inc. $ZTS

Key Points

• AlphaGrep UK Ltd acquired 17,696 Zoetis shares during the second quarter, valued at approximately $1.27 million. The position represents about 0.4% of its portfolio, while institutional investors collectively own 92.8% of Zoetis.
• Analyst sentiment is mixed, with eight Buy, nine Hold, and two Sell ratings. Zoetis has a consensus rating of Hold and an average price target of $107.43.
• Zoetis shares opened at $75.70, near their 52-week low of $71.00 and well below the 52-week high of $155.15. The company recently beat quarterly EPS estimates, reporting $1.87 versus the $1.85 consensus, although revenue declined slightly year over year.

AlphaGrep UK Ltd acquired a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 17,696 shares of the company's stock, valued at approximately $1,272,000. Zoetis makes up approximately 0.4% of AlphaGrep UK Ltd's portfolio, making the stock its 17th biggest holding.

Other hedge funds have also modified their holdings of the company. Prosperity Bancshares Inc acquired a new position in shares of Zoetis in the fourth quarter worth about $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Zoetis in the first quarter valued at $28,000. Elyxium Wealth LLC acquired a new stake in shares of Zoetis in the fourth quarter worth $32,000. Root Financial Partners LLC grew its holdings in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company's stock valued at $30,000 after buying an additional 103 shares in the last quarter. Finally, Wellington Grp LLC grew its holdings in shares of Zoetis by 6,675.0% during the first quarter. Wellington Grp LLC now owns 271 shares of the company's stock valued at $32,000 after buying an additional 267 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ZTS shares. TD Cowen reduced their price target on shares of Zoetis from $104.00 to $94.00 and set a "buy" rating for the company in a research report on Tuesday, August 25th. William Blair reiterated a "market perform" rating on shares of Zoetis in a research note on Thursday, August 6th. Barclays cut their target price on shares of Zoetis from $136.00 to $85.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 1st. Argus restated a "hold" rating on shares of Zoetis in a report on Wednesday, May 27th. Finally, Morgan Stanley set a $85.00 price target on shares of Zoetis in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $107.43.

Zoetis Stock Down 0.8%

NYSE ZTS opened at $75.70 on Friday. The business has a fifty day moving average price of $75.53 and a two-hundred day moving average price of $93.85. The stock has a market capitalization of $31.28 billion, a PE ratio of 12.47, a PEG ratio of 1.78 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis Inc. has a fifty-two week low of $71.00 and a fifty-two week high of $155.15.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business had revenue of $2.47 billion during the quarter, compared to analysts' expectations of $2.50 billion. During the same quarter in the prior year, the firm earned $1.76 EPS. The business's revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts expect that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source